MLS may also provide a model to evaluate therapies aimed at reducing TGFβ signaling in acquired fibrotic diseases, such as pulmonary, hepatic or renal fibrosis, scarring following burns or trauma, and scleroderma. Here, TGFB1 is linked to scleroderma.